Metabolic syndrome in type 1 diabetes mellitus in adults
https://doi.org/10.62751/2713-0177-2025-6-1-01
Abstract
Background. The prevalence of metabolic syndrome (MS) among people with type 1 diabetes mellitus (T1DM) varies widely depending on the criteria used and ranges from 6.4 to 57%. The relevance of studying the MS in T1DM is caused by the high risk of developing of micro and macrovascular complications. The current criteria for MS and the controversy over the inclusion of T1DM as a criterion do not provide reliability in diagnosing MS in this disease.
The aim. To assess the prevalence of MS in adults with T1DM and its impact on the course of the disease.
Materials and methods. A total of 134 patients over the age of 18 years were studied, including 67 (50%) men and 67 (50%) women. The median age was 33[19; 43] years, the median duration of diabetes was 13 [4; 27] years. MS was assessed according to the criteria of the 2009 Joint Interim Statement (JIS).
Results. MS was detected in 34 (25.4%) patients. The number of patients who did not have other criteria for MS except for T1DM was 57 (42.5%), 43 (32.1%) patients had 2 components of MS (one of the components in all was diabetes). Waist circumference >94 cm in men and > 80 cm in women, as well as blood pressure > 130 and 85 mm Hg were the most common components of MS (73.5 and 70.6% respectively). The insulin sensitivity coefficient was significantly lower in the group of people with MS (p=0.012). In patients with MS, only diabetic nephropathy was significantly more common (p = 0.019), while the differences in the frequency of retinopathy and neuropathy were statistically insignificant.
Conclusion. MS is a common condition in T1DM, which is based on insulin resistance. Presence of MS is associated with a risk of developing of diabetic nephropathy.
About the Authors
R. I. Malievskaya
Bashkir State Medical University
Russian Federation
Russian Federation
Ramsiya I. Malievskaya – MD, assistant professor
Scopus Author ID: 5892253710
Ufa
D. S. Avzaletdinova
Bashkir State Medical University
Russian Federation
Russian Federation
Diana S. Avzaletdinova – MD, PhD, associate professor
Scopus Author ID: 8317662600
Ufa
I. G. Nasretdinova
Bashkir State Medical University
Russian Federation
Russian Federation
Yulia G. Nasretdinova – resident of the Department of endocrinology
Ufa
I. Z. Urmanova
Arsk Central District Hospital
Russian Federation
Russian Federation
Indira Z. Urmanova – endocrinologist
Arsk
D. F. Iksanova
City Clinical Hospital № 5
Russian Federation
Russian Federation
Dinara F. Iksanova – endocrinologist
Ufa
References
1. Alberti KG, Eckel RH, Grundy SM et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120(16): 1640–45. doi: 10.1161/CIRCULATIONAHA.109.192644.
2. Huang Q, Yang D, Deng H et al. Association between metabolic syndrome and microvascular complications in Chinese adults with type 1 diabetes mellitus. Diabetes Metab J. 2022; 46(1): 93–103. doi: 10.4093/dmj.2020.0240.
3. Riaz A, Asghar S, Shahid S et al. Prevalence of metabolic syndrome and its risk factors influence on microvascular complications in patients with type 1 and type 2 diabetes mellitus. Cureus. 2024; 16(3): e55478. doi: 10.7759/cureus.55478.
4. Lee AS, Twigg SM, Flack JR. Metabolic syndrome in type 1 diabetes and its association with diabetes complications. Diabet Med. 2021; 38(2): e14376. doi: 10.1111/dme.14376.
5. Guo K, Zhang L, Ye J et al. Metabolic syndrome associated with higher glycemic variability in type 1 diabetes: A multicenter cross-sectional study in china. Front Endocrinol (Lausanne). 2022; 13: 972785. doi: 10.3389/fendo.2022.972785.
6. Colom C, Rull A, Sanchez-Quesada JL, Perez A. Cardiovascular disease in type 1 diabetes mellitus: Epidemiology and management of cardiovascular risk. J Clin Med. 2021; 10(8): 1798. doi: 10.3390/jcm10081798.
7. Lecumberri E, Nattero-Chavez L, Quinones Silva J et al. Impact of excluding hyperglycemia from international diabetes federation metabolic syndrome diagnostic criteria on prevalence of the syndrome and its association with microvascular complications, in adult patients with type 1 diabetes. Endocrine. 2022; 76(3): 601–11. doi: 10.1007/s12020-022-03041-8.
8. Леонова Н.В., Чумакова Г.А., Цирикова А.В., Пушкарева С.В. Влияние метаболического синдрома на риск развития осложнений сахарного диабета типа 1. Российский кардиологический журнал. 2015; (4): 55–58. doi: 10.15829/1560-4071-2015-4-55-58.
9. Wallace AS, Chang AR, Shin JI et al. Obesity and chronic kidney disease in US adults with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2022; 107(5): 1247–56. doi: 10.1210/clinem/dgab927.
10. Genua I, Franch-Nadal J, Navas E et al. Obesity and related comorbidities in a large population-based cohort of subjects with type 1 diabetes in Catalonia. Front Endocrinol (Lausanne). 2022; 13: 1015614. doi: 10.3389/fendo.2022.1015614.
11. Lee AS, Twigg SM, Flack JR. Metabolic syndrome in type 1 diabetes and its association with diabetes complications. Diabet Med. 2021; 38(2): e14376. doi: 10.1111/dme.14376.
12. Belete R, Ataro Z, Abdu A, Sheleme M. Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: A systematic review and meta-analysis. Diabetol Metab Syndr. 2021; 13(1): 25. doi: 10.1186/s13098-021-00641-8.
13. Agrawal S, Ganie MA, Goyal A et al. Metabolic syndrome in patients with type 1 diabetes mellitus at a tertiary centre in North India: A five year follow up study. Diabetes Metab Syndr. 2023; 17(6): 102781. doi: 10.1016/j.dsx.2023.102781.
14. Guo K, Zhang L, Ye J et al. Metabolic syndrome associated with higher glycemic variability in type 1 diabetes: A multicenter cross-sectional study in china. Front Endocrinol (Lausanne). 2022; 13: 972785. doi: 10.3389/fendo.2022.972785.
15. Sun H, Saeedi P, Karuranga S et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183: 109119. doi: 10.1016/j.diabres.2021.109119.
16. Lee YB, Han K, Kim B et al. High proportion of adult cases and prevalence of metabolic syndrome in type 1 diabetes mellitus population in Korea: A nationwide study. Diabetes Metab J. 2019; 43(1): 76–89. doi: 10.4093/dmj.2018.0048.
17. Ferreira-Hermosillo A, Ibarra-Salce R, Rodriguez-Malacara J, Molina-Ayala MA. Comparison of indirect markers of insulin resistance in adult patients with Double Diabetes. BMC Endocr Disord. 2020 15; 20(1): 87. doi: 10.1186/s12902-020-00570-z.
18. Chillaron JJ, Flores-Le-Roux JA, Goday A et al. Síndrome metabólico y diabetes mellitus tipo 1: prevalencia y factores relacionados [Metabolic syndrome and type-1 diabetes mellitus: prevalence and associated factors. Rev Esp Cardiol. 2010; 63(4): 423–29 (in Spanish)].
Review
For citations:
Malievskaya R.I., Avzaletdinova D.S., Nasretdinova I.G., Urmanova I.Z., Iksanova D.F. Metabolic syndrome in type 1 diabetes mellitus in adults. FOCUS. Endocrinology. 2025;6(1):6-12. (In Russ.) https://doi.org/10.62751/2713-0177-2025-6-1-01
Views:
85
Email this article 